Latest news with #NickTurner
IOL News
31-07-2025
- Entertainment
- IOL News
What's on in Cape Town this weekend: music, stars and a splash of adventure
Cape Town is set to bring all the vibes you need this weekend. From music, stargazing, and open water swimming, there's something for everyone to enjoy. Image: Instagram Big Folk Africa Enjoy a relaxed afternoon of live music featuring five of Cape Town's celebrated singer-songwriters: Nick Turner, Luna Paige, Stanley Sibande, Divine Mahara and Avril Mkansi (Dhahabu). Performing solo and in collaboration, each artist will include their home language in their set. The event takes place on a scenic outdoor patio with food and drinks available, offering a laidback and culturally rich musical experience. When: Sunday, August 3, from 1pm to 5pm. Where: Daisy Jones Bar in Stellenbosch The Cederberg Astronomical Observatory Enjoy a magical Saturday evening in the Cederberg under some of South Africa's darkest skies. The evening starts with an engaging presentation about the universe, followed by a guided stargazing experience where guests can observe clusters, nebulae, and galaxies through telescopes. It's an evening designed to spark curiosity and deepen your connection to the cosmos. When: Saturday, August 2, from 8pm to 10pm. Where: The Cederberg Astronomical Observatory in Citrusdal. Video Player is loading. Play Video Play Unmute Current Time 0:00 / Duration -:- Loaded : 0% Stream Type LIVE Seek to live, currently behind live LIVE Remaining Time - 0:00 This is a modal window. Beginning of dialog window. Escape will cancel and close the window. Text Color White Black Red Green Blue Yellow Magenta Cyan Transparency Opaque Semi-Transparent Background Color Black White Red Green Blue Yellow Magenta Cyan Transparency Opaque Semi-Transparent Transparent Window Color Black White Red Green Blue Yellow Magenta Cyan Transparency Transparent Semi-Transparent Opaque Font Size 50% 75% 100% 125% 150% 175% 200% 300% 400% Text Edge Style None Raised Depressed Uniform Dropshadow Font Family Proportional Sans-Serif Monospace Sans-Serif Proportional Serif Monospace Serif Casual Script Small Caps Reset restore all settings to the default values Done Close Modal Dialog End of dialog window. Advertisement Next Stay Close ✕ 36ONE Clifton Mile Swim The 36ONE Mile Swim is an open water event catering to swimmers of all levels, with three race options. The SplashDash is a 405m guided swim designed for beginners, offering a gentle introduction to open and cold-water swimming. The Lapper, at 750m, suits all skill levels and follows a set route with a 50-minute time limit. The main event, the Mile swim, is a 1,600m course aimed at intermediate and advanced swimmers, featuring scenic views and a more challenging route. All swims start and end in the shallows and follow a clockwise path around a series of buoys. When: The First Sunday of every month Time: 7.15am to 8am (SplashDash) | 8am to 8.45am (Lapper) | 9am to 10am (Mile swim) Where: Clifton 4th beach.
Business Upturn
09-07-2025
- Politics
- Business Upturn
Vera Institute of Justice Responds to Decision to Dismiss Complaint in Federal Class Action Lawsuit Challenging DOJ Termination of Safety and Justice Grants
By GlobeNewswire Published on July 9, 2025, 03:12 IST New York, New York, July 08, 2025 (GLOBE NEWSWIRE) — In response to the decision by the U.S. District Court for the District of Columbia to dismiss the complaint in a lawsuit challenging the Department of Justice's (DOJ) termination of $820 million in essential funding for community violence intervention, victim services, and youth and criminal justice reform, Nick Turner, president and director of the Vera Institute of Justice issued the following statement: 'Vera is deeply disappointed in the judge's decision to dismiss the complaint. As class representatives, Vera and the co-plaintiffs brought the lawsuit on behalf of hundreds of organizations across the country whose awards were abruptly and callously terminated by the DOJ's Office of Justice Programs, and should be restored. 'For decades, during both Republican and Democratic administrations, the Department of Justice has funded organizations like Vera and our co-plaintiffs to operate the programs and services that save lives and make communities safer. Indeed, Judge Amit Mehta acknowledged as much in his ruling, describing the rescinding of these grants as 'shameful' and 'likely to harm communities and individuals vulnerable to crime and violence.' While we do not agree with the court's overall decision, we must agree with Judge Mehta when he says that '[n]o federal agency, especially the Department of Justice, should conduct itself in such manner.' 'Today's ruling, while discouraging, is not the end of our fight and we are evaluating next steps.' Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
Yahoo
02-06-2025
- Business
- Yahoo
‘Transformational' new breast cancer drug could halt the growth of tumours
A new drug has been shown to halt the growth of certain breast cancer tumours, potentially delaying the need for chemotherapy, according to a new study. The Serena-6 trial found that camizestrant is effective in stopping cancer cells from using hormones to grow. One professor described the drug as representing "a pivotal moment in breast cancer care". Scientists said the trial marked the first global study demonstrating that early detection of cancer resistance through blood tests can significantly benefit patients. The study focused on patients with hormone-positive, HER2-negative breast cancer, which accounts for approximately 70 per cent of all cases. The results indicated that patients treated with camizestrant experienced a 56 per cent reduction in cancer progression compared to those receiving standard therapies. Doctors used a blood test to identify changes in the cancer's DNA, which signal the potential failure of current treatments. Upon detecting these signs, some patients were administered camizestrant, while others continued with their standard treatment. Those on camizestrant had their cancer stay the same and not get worse for much longer, 16 months on average, compared with about nine months for the others. The drug was safe for most patients but 1 per cent stopped taking it because of side effects. More than 3,000 patients from 23 countries took part in the study, which was funded by AstraZeneca and co-led by researchers at The Institute of Cancer Research in London. Co-principal investigator Professor Nick Turner, group leader in molecular oncology at The Institute of Cancer Research, London, said the drug is 'a pivotal moment in breast cancer care'. Professor Kristian Helin, chief executive of The Institute of Cancer Research said: 'The results of the Serena-6 trial represent more than a clinical milestone, they represent a transformational shift in how we approach precision medicine.' About 55,000 women are diagnosed with breast cancer in the UK every year and 11,500 will die from the disease, The Institute of Cancer Research said. The Serena-6 trial results were to be presented at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago on Sunday. Dr Catherine Elliott, director of research at Cancer Research UK, said: 'This study is a clear example of how blood tests are starting to transform cancer treatment. 'By tracking tiny traces of tumour DNA in the blood, researchers were able to spot early signs of treatment resistance and switch therapies before cancer had a chance to grow. 'It shows how circulating tumour DNA, or ctDNA, could help doctors make smarter, more timely treatment decisions. 'This approach could become an important part of how we personalise care for people with advanced breast cancer.'
Irish Examiner
01-06-2025
- Health
- Irish Examiner
New drug can help stop certain breast cancer tumours early, trial shows
A new drug can help stop certain breast cancer tumours before they grow, experts say. A trial called Serena-6 shows that camizestrant stops cancer cells from using hormones to grow, which helps patients stay well longer and delays the need for chemotherapy. It is the first worldwide study to show that using blood tests to find early signs of cancer resistance to treatment helps patients, scientists say. The study looked at patients who had hormone-positive, HER2-negative breast cancer, which is about 70% of cases. The results of the Serena-6 trial represent more than a clinical milestone, they represent a transformational shift in how we approach precision medicine Results showed patients given camizestrant reduced their chances of cancer progression by 56%, compared with just standard therapies. Doctors used a simple blood test to spot changes in the cancer's DNA that show whether current treatments might soon stop working. When they found these signs, some patients were given camizestrant, while others stayed on their usual treatment. Those on camizestrant had their cancer stay the same and not get worse for much longer, 16 months on average, compared with about nine months for the others. The drug was safe for most patients but 1% stopped taking it because of side effects. More than 3,000 patients from 23 countries took part in the study, which was funded by AstraZeneca and co-led by researchers at The Institute of Cancer Research in London. This study is a clear example of how blood tests are starting to transform cancer treatment Co-principal investigator Professor Nick Turner, group leader in molecular oncology at The Institute of Cancer Research, London, said the drug is 'a pivotal moment in breast cancer care'. Professor Kristian Helin, chief executive of The Institute of Cancer Research said: 'The results of the Serena-6 trial represent more than a clinical milestone, they represent a transformational shift in how we approach precision medicine.' The Serena-6 trial results were to be presented at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago on Sunday. Dr Catherine Elliott, director of research at Cancer Research UK, said: 'This study is a clear example of how blood tests are starting to transform cancer treatment. 'By tracking tiny traces of tumour DNA in the blood, researchers were able to spot early signs of treatment resistance and switch therapies before cancer had a chance to grow. 'It shows how circulating tumour DNA, or ctDNA, could help doctors make smarter, more timely treatment decisions. 'This approach could become an important part of how we personalise care for people with advanced breast cancer.'
Leader Live
01-06-2025
- Health
- Leader Live
New drug can help stop certain breast cancer tumours early, trial shows
A trial called Serena-6 shows that camizestrant stops cancer cells from using hormones to grow, which helps patients stay well longer and delays the need for chemotherapy. It is the first worldwide study to show that using blood tests to find early signs of cancer resistance to treatment helps patients, scientists say. The study looked at patients who had hormone-positive, HER2-negative breast cancer, which is about 70% of cases. Results showed patients given camizestrant reduced their chances of cancer progression by 56%, compared with just standard therapies. Doctors used a simple blood test to spot changes in the cancer's DNA that show whether current treatments might soon stop working. When they found these signs, some patients were given camizestrant, while others stayed on their usual treatment. Those on camizestrant had their cancer stay the same and not get worse for much longer, 16 months on average, compared with about nine months for the others. The drug was safe for most patients but 1% stopped taking it because of side effects. More than 3,000 patients from 23 countries took part in the study, which was funded by AstraZeneca and co-led by researchers at The Institute of Cancer Research in London. Co-principal investigator Professor Nick Turner, group leader in molecular oncology at The Institute of Cancer Research, London, said the drug is 'a pivotal moment in breast cancer care'. Professor Kristian Helin, chief executive of The Institute of Cancer Research said: 'The results of the Serena-6 trial represent more than a clinical milestone, they represent a transformational shift in how we approach precision medicine.' About 55,000 women are diagnosed with breast cancer in the UK every year and 11,500 will die from the disease, The Institute of Cancer Research said. The Serena-6 trial results were to be presented at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago on Sunday. Dr Catherine Elliott, director of research at Cancer Research UK, said: 'This study is a clear example of how blood tests are starting to transform cancer treatment. 'By tracking tiny traces of tumour DNA in the blood, researchers were able to spot early signs of treatment resistance and switch therapies before cancer had a chance to grow. 'It shows how circulating tumour DNA, or ctDNA, could help doctors make smarter, more timely treatment decisions. 'This approach could become an important part of how we personalise care for people with advanced breast cancer.'
